(Q37967507)

26 August 2017

Treatment of brain metastases: chemotherapy (English)

1 reference

26 August 2017

1 reference

1 reference

Sean A Grimm

1

1 reference

26 August 2017

1 February 2012

1 reference

26 August 2017

Current Oncology Reports

1 reference

26 August 2017

14

1 reference

26 August 2017

1

1 reference

26 August 2017

85-90

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-011-0211-y

26 August 2017

0 references

cites work

The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

The role of the organ microenvironment in brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Drug interactions between chemotherapeutic regimens and antiepileptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Optimizing therapy of seizures in patients with brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Current management of brain metastases, with a focus on systemic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Motexafin gadolinium: a novel radiosensitizer for brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

CNS metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Systemic treatment in breast-cancer patients with brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Response of brain metastases from breast cancer to systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Chemotherapy induces regression of brain metastases in breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Capecitabine therapy of central nervous system metastases from breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Longterm remission of multiple brain metastases with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Brain metastases: the HER2 paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

HER2 in brain metastases: issues of concordance, survival, and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0211-Y

Response of brain metastases from breast cancer to megestrol acetate: A case report

21 January 2018

1 reference

12 December 2020

Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases

1 reference

12 December 2020

The biology of brain metastases-translation to new therapies

1 reference

12 December 2020

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

1 reference

12 December 2020

1 reference

12 December 2020

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

1 reference

12 December 2020

Brain metastases. Histology, multiplicity, surgery, and survival

1 reference

12 December 2020

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)

1 reference

12 December 2020

10.1007/S11912-011-0211-Y

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22161303